| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/23/2005 | WO2005023792A3 Macrocyclic compounds useful as pharmaceuticals |
| 06/23/2005 | WO2005023232A3 Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| 06/23/2005 | WO2005023083A3 Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| 06/23/2005 | WO2005022116A3 Antioxodant sensor, methods and compositions |
| 06/23/2005 | WO2005016885A3 COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| 06/23/2005 | WO2005014584A9 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 06/23/2005 | WO2005013945A3 Medicaments for inhalation comprising steroids and a betamimetic |
| 06/23/2005 | WO2005011652A3 Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
| 06/23/2005 | WO2005007601A3 Substituted arylthiourea derivatives useful as inhibitors of viral replication |
| 06/23/2005 | WO2005000406A3 Treatment of amyloid- and epileptogenesis-associated diseases |
| 06/23/2005 | WO2005000213A8 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
| 06/23/2005 | WO2004109768A3 Methods and intermediates for the synthesis of dipyrrin-substituted porphyrinic macrocycles |
| 06/23/2005 | WO2004101510B1 Polymorphs of cabergoline |
| 06/23/2005 | WO2004100880A3 Controlled release formulation of erythromycin derivatives |
| 06/23/2005 | WO2004098625A3 Medical use of inhibitors of glutaminyl and glutamate cyclases |
| 06/23/2005 | WO2004089369B1 Methods and means for treating protein conformational disorders |
| 06/23/2005 | WO2004089307A8 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| 06/23/2005 | WO2004078928A3 T cell regulation |
| 06/23/2005 | WO2004071538A3 Topical delivery of cosmetic agents |
| 06/23/2005 | WO2004055026A8 Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 06/23/2005 | WO2004041258A8 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 06/23/2005 | WO2004039327A8 Use of equol for treating androgen mediated diseases |
| 06/23/2005 | WO2004024081A3 Acetyl 2-hydroxy-1,3 diaminoalkanes |
| 06/23/2005 | US20050137684 Stent with therapeutically active drug coated thereon |
| 06/23/2005 | US20050137679 Modified stent useful for delivery of drugs along stent strut |
| 06/23/2005 | US20050137414 New aminopropylphosphinic acids |
| 06/23/2005 | US20050137405 Reacting o-chlorobenzaldehyde with an alkyl 4-(phthalimido)ethoxy)acetoacetate to yield alkyl 2-(o-chlorobenzylidene)-4-(2-phthalimidoethoxy)acetoacetate which upon reacting with an alkyl -3-aminocrotonate yields a phtahalimiamlodipine; good yields and purity; useful as reference standards or markers |
| 06/23/2005 | US20050137399 A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields |
| 06/23/2005 | US20050137398 E. g., 3-[(4-phenoxyphenyl)thio]quinuclidine, 3-[(5-phenoxypyridin-2-yl)oxy]quinuclidine, N-(4-(1-azabicyclo[2.2.2]oct-3-yloxy)- phenyl] -N,N-bis(1-benzothien-3-yl)amine, et al: selectively modulating alpha 7-nicotinic acetylcholine; cognitive, neurodegenerative and atypical antipsychotic disorders |
| 06/23/2005 | US20050137395 E.g., 6-[(7-iodoquinolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide; antiproliferative agent for hyperproliferative disorders being either cancerous or noncancerous; vasculogenesis or angiogenesis inhibitors; adminstered with hypotensive agent, antitumor agents, mitotic inhibitors and others |
| 06/23/2005 | US20050137334 Composite nanospheres and their conjugates with biomolecules |
| 06/23/2005 | US20050137274 Inverse high internal phase emulsion (I-HIPE) foam; enables replacement of the oils with supercritical fluids that are non-toxic, environmentally friendly, more soluble and have little or no interaction with the foaming material |
| 06/23/2005 | US20050137265 For treating gastroparesis; does not have to be taken with liquids which helps ensure proper dosage in patients with nausea |
| 06/23/2005 | US20050137264 Modafinil compositions |
| 06/23/2005 | US20050137263 e.g., 2-[(4-Ethyl-2-fluorophenyl)amino]-3,4-difluoro-N-(2-hydroxyethoxy)benzamide, is administered to treat arthritis |
| 06/23/2005 | US20050137262 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 06/23/2005 | US20050137261 Administering to a subject in need thereof an effective amount of 1,4-dihydroxy-2-naphthoic acid or a salt thereof for therapy of an inflammatory bowel disease |
| 06/23/2005 | US20050137260 and optionally glycerin; treatment of skin aging and/or abnormal skin pigmentation |
| 06/23/2005 | US20050137259 Corosolic acid, acylcorosolic acids, maslinic acid and/or acylmaslinic acids as early insulin secretion stimulator(s); extracts from banaba plant; side effect reduction over current antidiabetes agents |
| 06/23/2005 | US20050137258 Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium |
| 06/23/2005 | US20050137257 Treating eczema and/or psoriasis |
| 06/23/2005 | US20050137256 arachidonic acid derivatives such as the methyl ester, the ethyl ester, triglyceride, or the sodium or arginine salts; increasing the serum level of the prostaglandin PGF2alpha |
| 06/23/2005 | US20050137255 Novel crystal form that is stable, water soluble, and nonhygroscopic at a relative humidity less than 70% |
| 06/23/2005 | US20050137253 Non-alpha tocopherol such as gamma-tocopherol and an omega-3 fatty acid such as docosahexaenoic acid; e.g. end-stage renal disease, diabetes, respiratory system disorders such as asthma, lupus |
| 06/23/2005 | US20050137251 Dexanabinol and dexanabinol analogs regulate inflammation related genes |
| 06/23/2005 | US20050137249 Cyclization at the 5,6-position of the benzo[e]naphtho[3,2-h]azulene, oxepane or thiepane with a mercaptoacetic acid ester followed by etherification, amination or sulfiding at the 2-position; antiarthritic and antiinflammatory agents, analgesics; biosynthesis inhibitors of interleukin-1; nontoxic |
| 06/23/2005 | US20050137247 Methods and compositions for treatment of hypertension |
| 06/23/2005 | US20050137245 Novel fused pyrrolocarbazoles |
| 06/23/2005 | US20050137242 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 06/23/2005 | US20050137239 Thiazole derivatives |
| 06/23/2005 | US20050137237 Triazolo-epothilones |
| 06/23/2005 | US20050137235 Combination of flupirtine and tramadol |
| 06/23/2005 | US20050137234 Histone deacetylase inhibitors |
| 06/23/2005 | US20050137233 Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide |
| 06/23/2005 | US20050137232 Histone deacetylase inhibitors |
| 06/23/2005 | US20050137230 Factor Xa-inhibitors; preventing thromboembolic illnesses and tumors; 2-amino-N-(2'-methylsulfonylbiphenyl-4-yl)-3-phenylpropionamide |
| 06/23/2005 | US20050137228 Benzyl sulfonamide derivatives |
| 06/23/2005 | US20050137227 Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof |
| 06/23/2005 | US20050137226 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| 06/23/2005 | US20050137224 2-Cyanopyrrolidinecarboxamide compound |
| 06/23/2005 | US20050137223 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 06/23/2005 | US20050137222 Treatment of insomnia in human patients |
| 06/23/2005 | US20050137221 Keratinocyte-proliferative diseases; inhibitor of solubilization of Epidermal Growth Factor; 3,4,5-trihydroxy-1-(4'-methoxybenzenesulfonyl)-piperidine-2-carboxylic acid hydroxamide; 7-acetoxy-5-(4'-methoxybenzenesulfonyl)-2,2-dimethyl-h exahydro-[1,3]dioxolo[4,5-c]pyridine-6-carboxy ester intermediate |
| 06/23/2005 | US20050137220 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| 06/23/2005 | US20050137219 alzheimer's disease; schizophrenia |
| 06/23/2005 | US20050137218 Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| 06/23/2005 | US20050137217 Spirocyclic quinuclidinic ether derivatives |
| 06/23/2005 | US20050137216 Heterocyclic sodium/proton exchange inhibitors and method |
| 06/23/2005 | US20050137215 Antiarthritic and antiinflammatory agents; analgesics; the proline derivatives do not displace gabapentin from alpha-2-delta receptors |
| 06/23/2005 | US20050137214 Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example |
| 06/23/2005 | US20050137213 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis; antiproliferative, anticarcinogenic, antimetabolic agents; tubulin and topoisomerase II inhibitors; fungicides; synergistic administration with other anticarcinogenic agents |
| 06/23/2005 | US20050137212 Hppars activators |
| 06/23/2005 | US20050137211 Phenyl-piperazine derivatives as modulators of muscarinic receptors |
| 06/23/2005 | US20050137210 Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders |
| 06/23/2005 | US20050137209 Beta hydroxysteroid dehydeogenase for cardiovascular disorders |
| 06/23/2005 | US20050137208 Chemical compounds |
| 06/23/2005 | US20050137207 Inhibitor of prenylprotein tranferase for cancer and tumor treatment |
| 06/23/2005 | US20050137206 6-hydroxy-8-[4-,4-[2-pyrimidinyl-piperazinyl]butyl]-8-aza-spiro-[4.5]-7,9-dione(6-hydroxy buspirone) as antidepressants |
| 06/23/2005 | US20050137205 Antiinflammatory agents for treatment of skin disorders |
| 06/23/2005 | US20050137203 Conditions useful for treatment of cognition activators, neurodegeneration or schizophrenia |
| 06/23/2005 | US20050137201 Compositions useful as inhibitors of protein kinases |
| 06/23/2005 | US20050137200 Potassium channel modulators; antiarrhythmia agents |
| 06/23/2005 | US20050137199 Aza-quinolinol phosphonate integrase inhibitor compounds |
| 06/23/2005 | US20050137198 Stable hydrazalazine pharmaceutical compositions |
| 06/23/2005 | US20050137196 Medical devices employing triazine compounds and compositions thereof |
| 06/23/2005 | US20050137195 Thermodynamically stable |
| 06/23/2005 | US20050137194 Treatment of overactive bladder with opiods |
| 06/23/2005 | US20050137193 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide |
| 06/23/2005 | US20050137192 Use of compounds such as 4-bromo-9a-butyl-8-chloro-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one to treat depression |
| 06/23/2005 | US20050137191 Nitrate esters and their use for mitigating cellular damage |
| 06/23/2005 | US20050137190 Compositions useful as inhibitors of voltage-gated sodium channels |
| 06/23/2005 | US20050137189 For therapy of Gram-positive bacterial infection |
| 06/23/2005 | US20050137188 Heterocyclic compounds |
| 06/23/2005 | US20050137187 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| 06/23/2005 | US20050137186 Tetrahydrobenzazepines and their use |
| 06/23/2005 | US20050137185 Combinations of drugs for the treatment of neoplasms |
| 06/23/2005 | US20050137184 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 06/23/2005 | US20050137183 Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients |
| 06/23/2005 | US20050137181 Administering purine nucleoside for treatment of arthritis inflammation |
| 06/23/2005 | US20050137180 Porphrins or azaporprins for photosensitizing therapy or photodetection with azaporprins for cardiovascular disorders and coordination with metals |